Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety of Nelonicline in Alzheimer's Disease Extension Study
NCT01676935Phase 2Terminated
- Sponsor
- AbbVie Inc.
- Start
- Aug 2012
- Primary completion
- Mar 2014
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of nelonicline in Alzheimer's disease (AD), sponsored by AbbVie Inc.. Started Aug 2012; status: terminated.
02
Drugs
nelonicline
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01676935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01676935.